| Literature DB >> 25471683 |
Daniel Soltanifar1, Brendan Carvalho, Pervez Sultan.
Abstract
PURPOSE: Malaria is a life-threatening infectious disease caused by the Plasmodium parasite. Increased global travel has resulted in an escalation in the number of imported cases seen in developed countries. Patients with malaria may present for surgery in both endemic and non-endemic countries. This article reviews the perioperative considerations when managing patients with malaria. SOURCE: A literature review of anesthesia, perioperative care, and malaria-related articles was performed using the MEDLINE(®), EMBASE™, and Web of Science databases to identify relevant articles published in English during 1945-2014. Of the 303 articles matching the search criteria, 265 were excluded based on title and abstract. Eleven of the remaining 38 articles were relevant to anesthesia/perioperative care, and 27 articles were identified as having direct relevance to critical care medicine. PRINCIPALEntities:
Mesh:
Substances:
Year: 2014 PMID: 25471683 PMCID: PMC7102007 DOI: 10.1007/s12630-014-0286-7
Source DB: PubMed Journal: Can J Anaesth ISSN: 0832-610X Impact factor: 5.063
World Health Organization diagnostic criteria for severe falciparum malaria
| Clinical Features | Laboratory Findings |
|---|---|
| Impaired consciousness or unrousable coma | Hypoglycemia (blood glucose < 2.2 mmol·L−1 or < 40 mg·dL−1) |
| Prostration, i.e., generalized weakness so the patient is unable to sit up or walk without assistance | Metabolic acidosis (plasma bicarbonate < 15 mmol·L−1) |
| Failure to feed | Severe normocytic anemia (Hb < 5 g·dL−1, packed cell volume < 15%) |
| Multiple convulsions | Hemoglobinuria |
| Deep breathing, respiratory distress | Hyperparasitemia > 2%/100,000/μL in low intensity transmission area or > 5%/ 100,000/μL in areas of high stable malaria transmission intensity |
| Circulatory collapse or shock; Systolic blood pressure < 70 mmHg in adults and < 50 mmHg in children | Hyperlactatemia (lactate > 5 mmol·L−1) |
| Clinical jaundice and evidence of other vital organ dysfunction | Renal impairment (serum creatinine > 265 μmol·L−1) |
| Hemoglobinuria | |
| Abnormal spontaneous bleeding | |
| Pulmonary edema (radiological) |
Hb = hemoglobin. The presence of one or more of the above clinical or laboratory features with confirmed Plasmodium falciparum parasitemia classifies the patient as suffering from severe malaria
Adapted from WHO guidelines for the treatment of malaria22
WHO recommendations for the treatment of malaria
| Type of malaria infection | 1st line treatment | 2nd line treatments |
|---|---|---|
| Uncomplicated | Artemisinin-based combination therapy* (ACT)** | 1) Alternative ACT known to be effective in that region 2) Artesunate plus doxycycline or tetracycline or clindamycin 3) Quinine plus doxycycline or tetracycline or clindamycin |
| Severe | Intravenous artesunate | Intravenous artemether or intravenous quinine if intravenous artesunate is not available |
|
| Chloroquine plus primaquine*** for quinine-sensitive strains | ACT plus primaquine for quinine-resistant strains |
|
| Chloroquine plus primaquine | |
|
| Chloroquine |
ACTs recommended include artemether plus lumefantrine, artesunate plus amodiaquine, artesunate plus mefloquine, and artesunate plus sulfadoxine-pyrimethamine
*For travellers returning to non-endemic countries atovaquone-proguanil, artemether-lumefantrine or quinine plus doxycycline or quinine plus clindamycin is recommended
**ACTs are unavailable in Canada and the CATMET recommended first-choice therapy for uncomplicated falciparum malaria is oral atovaquone-proguanil (Malarone™)
***Primaquine required for clearance of liver-stage hypnozoites seen only in vivax and ovale
ACT = artemisinin-based combination therapy; CATMET = Committee to Advise on Tropical Medicine and Travel
Adapted from WHO guidelines for the treatment of malaria22
Pharmacology of some of the main antimalarial drugs
| Drug | Anti-malarial mechanism of action | Formulations | Pharmacokinetics | Toxicity | Interactions |
|---|---|---|---|---|---|
Artemisinin Extracted from the leaves of sweet wormwood, | Potent blood schizonticide; kills all stages of the asexual parasite by inhibition of an essential calcium ATPase (PfATPase6) | Wide variety of formulations for oral, rectal, and parenteral use | Converted to inactive metabolites by CYP2B6 Potent inducer of its own metabolism Half-life (or t ½) = 1 hr | Usually safe and well tolerated Anaphylaxis in 1/3,000 cases QT prolongation and bradycardia have been reported | None known |
Artesunate Sodium salt of the hemisuccinate ester of artemisinin
| Same as for Artemisinin | Tablets, ampoules for intramuscular, intravenous injection, and rectal capsules | Rapidly absorbed Converted almost entirely to the active metabolite dihydroartemisinin t ½ = 45 min No dose reduction with renal or hepatic impairment | As for Artemisinin Some reports of delayed hemolytic reactions and neutropenia | None known |
Chloroquine 4 aminoquinoline | Interferes with parasite heme detoxification Ineffective in | Tablets and ampoules for intramuscular or intravenous injection | Rapid absorption when given orally, intramuscularly, or subcutaneously Eliminated very slowly by the kidneys t ½ = 1-2 months | Low safety margin and very dangerous in overdose with multiple side-effects Unpleasant taste Rarely central nervous system toxicity, including convulsions and mental changes Acute overdose can cause cardiac arrhythmias, hypotension, and hypokalemia | Risk of arrhythmias with drugs that prolong the QT interval Risk of acute dystonic reactions with metronidazole Reduced bioavailability of ampicillin Antagonist of antiepileptic effects of carbamazepine and sodium valproate |
Primaquine 8 aminoquinoline | Effective against intrahepatic forms of all types of malaria parasite Exact mechanism of action unknown | Tablets | Well absorbed from gastrointestinal tract t ½ = 3-6 hr Metabolized in the liver | Hemolytic anemia in patients with Glucose-6-phosphate dehydrogenase deficiency Abdominal pain Methemoglobinemia | Concomitant drugs liable to induce hemolysis or bone marrow suppression should be avoided |
Quinine Alkaloid derived from bark of the Cinchona tree L-stereoisomer of quinidine | Proposed mechanism is inhibition of parasite heme detoxification in the food vacuole Acts principally on the mature trophozoite stage of parasite development | Tablets and ampoules for intravenous injections | Pharmacokinetic properties affected by the severity of malaria Rapid absorption with wide volume of distribution Metabolized by CYP3A4 in liver with polar metabolites excreted in urine Accumulates in renal failure | Toxicity causes a complex of symptoms known as cinchonism, including tinnitus, impaired high-tone hearing, headache, nausea, dizziness, dysphoria, and disturbed vision Hyperinsulinemic hypoglycemia in severe malaria which is particularly common in pregnancy Hypotension and cardiac arrest may result from rapid intravenous injection, therefore should be given by infusion only Prolonged QT interval and arrhythmias | Quinine increases the plasma concentration of digoxin Avoid other drugs that prolong the QT interval |
| Atovaquone-Proguanil (Malarone™) | Combination of drugs work synergistically Inhibits | Tablets (containing 250 mg of Atovaquone and 100 mg of Proguanil) | Atovaquone is 99% protein bound t ½ = 66-70 hr due to enterohepatic recycling Excreted in feces as unchanged drug Proguanil is 75% protein bound. 50% excreted in urine Accumulates in renal failure with dose reduction needed | Side effects are mainly gastrointestinal including nausea vomiting, diarrhoea and abdominal pain. Can cause transient rise in amylase and transaminases | Atovaquone can displace other highly protein-bound drugs from their protein binding sites. Proguanil potentiates the effects of warfarin |
Adapted from WHO guidelines for the treatment of malaria22
Perioperative considerations for patients on quinine therapy
| Effect | Mechanism | Management strategy |
|---|---|---|
| Hypoglycemia (may be profound in children and pregnancy) | Quinine is a potent stimulator of pancreatic insulin release | Regular blood glucose monitoring is essential and should be performed with any decrease in level of consciousness or convulsions. Consider continuous intravenous dextrose infusion to prevent hypoglycemia. |
| Cardiac arrhythmia (may be life-threatening in elderly or those with cardiovascular disease) | Quinine blocks cardiac fast Na+ channels prolonging action potential duration and repolarization time | A baseline electrocardiogram and continuous cardiac monitoring to exclude lengthening of the QT interval is essential in patients receiving intravenous quinine therapy. |
| Prolonged neuromuscular blockade | Quinine affects neuromuscular transmission presynaptically by blocking voltage-gated Na+ channels and postsynaptically by potentiating depolarization. The overall effect is to reduce motor end-plate excitability. | Monitor depth of neuromuscular blockade with nerve stimulator to ensure full reversal prior to extubation. Prolonged neuromuscular blockade may necessitate postoperative ventilation until full resolution of blockade. |
Recommended preoperative investigations and assessment in patients with malaria
| System | Investigation/Assessment | Indication |
|---|---|---|
| Hematology | Complete blood count | Anemia / Thrombocytopenia |
| Blood film | Degree of parasitemia | |
| Coagulation profile | Evidence of DIC | |
| Blood type and crossmatch | Need for blood transfusion more likely in the presence of anemia | |
| Renal | Urea, creatinine, and urine output | Consider need for preoperative RRT |
| Electrolytes, including Mg2+ and Ca2+ | Hyperkalemia and hyponatremia are the most common electrolyte disturbances | |
| Hepatic | Liver function tests, albumin | Fluid overload will be more likely in the presence of hypoalbuminemia |
| Respiratory | CXR, ABG, Pulse Oximetry | Respiratory failure is common in severe |
| Cardiac | ECG | QT interval is prolonged in patients on quinine |
| Echocardiogram | Myocardial dysfunction occurs in severe | |
| Neurological | GCS and Pupils | Evidence of cerebral malaria or raised ICP in severe |
| Metabolic | Blood glucose | Hypoglycemia is common in severe |
| Lactate | Acidosis is a predictor of disease severity |
DIC = disseminated intravascular coagulation; RRT = renal replacement therapy; CXR = chest radiograph; ABG = arterial blood gas; ECG = electrocardiogram; GCS = Glasgow Coma scale; ICP = intracranial pressure
Intraoperative anesthetic goals in patients with malaria
| Anesthesia | Goals | Suggested management strategies |
|---|---|---|
| Induction | Hemodynamically stable induction without increased CBF Avoid surges in ICP and hypercapnia | Propofol Avoid Ketamine Ensure full neuromuscular blockade prior to intubation Obtund the autonomic response to intubation Start ventilation as soon as intubation is confirmed |
| Maintenance | Avoid cerebral vasodilation /raised ICP | Sevoflurane/Propofol (less CBF increase with Propofol) Maintain normocapnia 15° head-up position Avoid endotracheal tube ties Regular assessment of pupils |
| Lung protective ventilation strategy | TV 6 mL·kg−1 Application of PEEP Limit plateau pressures < 30 cm H2O | |
| Avoid fluid overload | TEE/CVP guided fluid therapy Early use of inotropes preferential to excessive fluid boluses | |
| Avoid hypoglycemia | 10% Dextrose as maintenance infusion Measure blood glucose twice hourly | |
| Appropriate transfusion of blood products | Blood transfusion if hemoglobin < 7 g·dL−1 or hematocrit < 20% Platelet transfusion for surgery if platelets < 50 × 109·L−1 | |
| Extubation | Safe and appropriate extubation | Ensure resolution of neuromuscular blockade Prolonged blockade in the presence of quinine may require postoperative ventilation Minimize increases in ICP on extubation Avoid excessive use of sedative drugs Short-acting opioids preferred |
CBF = cerebral blood flow; ICP = intracranial pressure; TV = tidal volume; PEEP = positive end expiratory pressure; TEE = transesophageal echocardiography; CVP = central venous pressure